Trialssurvodutideboehringer ingelheimmashcirrhosis

Boehringer recruiting for Phase III survodutide trial in MASH cirrhosis

LIVERAGE-Cirrhosis randomizes compensated NASH/MASH cirrhosis patients 2:1 to weekly survodutide or placebo for up to four and a half years.

By Priya Raman · Science Reporter

Oct 14 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT06632457, sponsored by Boehringer Ingelheim, started November 2024 and is recruiting adults with compensated NASH/MASH cirrhosis and BMI at least 27, or 25 for Asian participants, to test liver-related clinical outcomes.
02Survodutide is a weekly injected glucagon/GLP-1 dual agonist, and a cirrhosis outcomes trial extends incretin testing into a population excluded from most obesity studies.
03Participants with other chronic liver disease or high alcohol intake are excluded; follow-up runs up to 4.5 years, so outcome data are years away.

From the source

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457 · PHASE3 · RECRUITING · Sponsor: Boehringer Ingelheim · Conditions: Metabolic Dysfunction Associated Steatohepatitis.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT06632457